OnkoMed GbR Dr. M. Neise, Dr. A. Lollert, Dr. D. Neise
- Address
- Dießemer Bruch 79, 47805 Krefeld, Germany
OnkoMed GbR Dr. M. Neise, Dr. A. Lollert, Dr. D. Neise
OnkoMed GbR is a specialized oncology research center focused on advancing treatment options for hematologic malignancies. The center demonstrates particular expertise in multiple myeloma research, investigating novel therapeutic approaches for patients who are not candidates for stem cell transplantation.
- First-line treatment protocols for transplant-ineligible multiple myeloma patients
- Daratumumab-based combination therapies with standard chemotherapy regimens
- Relapse management strategies in hematologic cancers
The research team evaluates innovative treatment sequences, including daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone, aiming to optimize both safety and efficacy outcomes. Their work addresses critical needs in managing elderly or medically ineligible patient populations who require effective yet tolerable therapeutic options for blood cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in OnkoMed GbR Dr. M. Neise, Dr. A. Lollert, Dr. D. Neise
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone for Transplant-Ineligible Multiple Myeloma Patients | University Of Cologne | Phase II | Not Recruiting | May 2021 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Daratumumab | 1 | Unknown | 2021-05-31 | 2021-05-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.